In short
Clinical trials are investigating Levodropropizine in people with advanced respiratory disease and dyspnea, which means a feeling of shortness of breath. These studies look at how well the treatment approach works and whether it is safe and tolerable in this patient group.
Key points
- Clinical trial data show one authorised Phase 2 study of Levodropropizine in people with advanced respiratory disease and dyspnea. The study is interventional and plans to enroll 114 participants. It focuses on treatment effects in shortness of breath and on safety and tolerability measures. The main reported outcome is the safety and tolerability of a single inhaled dose of furosemide, measured by treatment-related adverse events. The study also includes oral Levodropropizine as part of the intervention plan.
Trial overview
The available trial data describe one authorised interventional study of Levodropropizine in people with dyspnea, which means shortness of breath.
The study is titled INFURO and it examines the impact of inhaled furosemide and orally administered Levodropropizine on dyspnea perception in patients with advanced respiratory diseases.
Who is being studied
This trial targets patients with advanced lung disease and dyspnea, so the study population has serious breathing problems related to respiratory illness.
The planned enrollment is 114 participants, which means the researchers plan to include 114 people in the study.
Study design and phase
This is a Phase 2 trial, a stage that usually looks for early signs of benefit while continuing safety checks in a defined patient group.
The study status is Authorised, which means it has received permission to proceed according to the source data.
The intervention plan includes oral use of Levodropropizine, along with inhaled furosemide and sodium chloride inhalation as listed in the trial record.
What is being measured
The main outcome is safety and tolerability of a single dose of inhaled furosemide, measured by the number and type of treatment-related adverse events.
The study also focuses on dyspnea perception, meaning how patients feel or notice their shortness of breath during the study.
Trial details
The trial record lists three interventions: sodium chloride by inhalation, furosemide by inhalation, and Levodropropizine by mouth.
Because the source data provide only one trial, the current clinical research picture for Levodropropizine in this set is limited to this single Phase 2 study in advanced respiratory disease.